 RADNOR, Pa., March 29, 2021 PRNewswire -- NeuroRx, Inc. today reports 60-day results of the Phase 2b3 trial of intravenously-administered ZYESAMITM aviptadil acetate for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG SIX:RLF, OTCQB:RLFTF. 